ANXA1 and central nervous system cancer: Glioma patients with higher ANXA1 expression, including LGG and GBM samples, had a significantly shorter survival rate than those with a lower expression from the TCGA database (P < 0.05) (Figures 5A,B); The survival analysis results of CGGA were consistent with those of TCGA (P < 0.01) (Figures 5C,D).